K2M Group Holdings, Inc. (NASDAQ:KTWO)‘s stock had its “buy” rating reaffirmed by Royal Bank Of Canada in a report issued on Thursday. They presently have a $26.00 price objective on the medical device company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 5.01% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on KTWO. BidaskClub raised shares of K2M Group Holdings from a “hold” rating to a “buy” rating in a research report on Wednesday. Cowen and Company reaffirmed a “buy” rating and set a $26.00 price objective on shares of K2M Group Holdings in a research report on Wednesday. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of K2M Group Holdings in a research report on Tuesday, July 11th. Zacks Investment Research raised shares of K2M Group Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, March 30th. Finally, JMP Securities reissued an “outperform” rating and issued a $30.00 price target (up from $27.00) on shares of K2M Group Holdings in a research report on Wednesday, June 28th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $25.88.

Shares of K2M Group Holdings (NASDAQ KTWO) traded up 0.97% during trading on Thursday, hitting $25.00. The stock had a trading volume of 285,227 shares. K2M Group Holdings has a one year low of $15.45 and a one year high of $25.18. The stock’s market cap is $1.06 billion. The stock’s 50 day moving average price is $23.57 and its 200-day moving average price is $21.63.

K2M Group Holdings (NASDAQ:KTWO) last released its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The firm had revenue of $61.89 million for the quarter, compared to analysts’ expectations of $60.10 million. K2M Group Holdings had a negative return on equity of 16.02% and a negative net margin of 17.48%. Analysts expect that K2M Group Holdings will post ($0.80) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/07/20/royal-bank-of-canada-reiterates-buy-rating-for-k2m-group-holdings-inc-ktwo.html.

In other K2M Group Holdings news, CFO Gregory S. Cole sold 42,947 shares of K2M Group Holdings stock in a transaction on Friday, June 16th. The shares were sold at an average price of $22.80, for a total value of $979,191.60. Following the transaction, the chief financial officer now directly owns 87,425 shares in the company, valued at $1,993,290. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John Philip Md Kostuik sold 50,000 shares of K2M Group Holdings stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $22.70, for a total transaction of $1,135,000.00. Following the completion of the transaction, the insider now owns 199,107 shares in the company, valued at $4,519,728.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 95,805 shares of company stock valued at $2,178,713. 5.80% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of KTWO. TimesSquare Capital Management LLC raised its position in K2M Group Holdings by 44.0% in the first quarter. TimesSquare Capital Management LLC now owns 2,197,020 shares of the medical device company’s stock worth $45,061,000 after buying an additional 671,120 shares in the last quarter. Wellington Management Group LLP raised its position in K2M Group Holdings by 10.4% in the first quarter. Wellington Management Group LLP now owns 1,875,913 shares of the medical device company’s stock worth $38,475,000 after buying an additional 175,998 shares in the last quarter. Schroder Investment Management Group raised its position in K2M Group Holdings by 5.9% in the first quarter. Schroder Investment Management Group now owns 1,535,669 shares of the medical device company’s stock worth $31,443,000 after buying an additional 85,476 shares in the last quarter. JPMorgan Chase & Co. raised its position in K2M Group Holdings by 54.3% in the first quarter. JPMorgan Chase & Co. now owns 1,409,360 shares of the medical device company’s stock worth $28,906,000 after buying an additional 495,749 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in K2M Group Holdings by 13.8% in the first quarter. Vanguard Group Inc. now owns 1,379,090 shares of the medical device company’s stock worth $28,285,000 after buying an additional 167,036 shares in the last quarter. Institutional investors own 98.75% of the company’s stock.

About K2M Group Holdings

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group Holdings (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.